NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 52 filers reported holding NEUROCRINE BIOSCIENCES INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,587 | -100.0% | 1,000 | -100.0% | 0.00% | -100.0% |
| Q4 2020 | $64,681,000 | -0.6% | 46,390,000 | 0.0% | 0.06% | -15.8% |
| Q3 2020 | $65,053,000 | -38.2% | 46,390,000 | -23.2% | 0.08% | -37.7% |
| Q2 2020 | $105,347,000 | +23.9% | 60,425,000 | -5.5% | 0.12% | +7.0% |
| Q1 2020 | $85,025,000 | -24.2% | 63,975,000 | -11.4% | 0.11% | +10.7% |
| Q4 2019 | $112,242,000 | +22.7% | 72,175,000 | +8.4% | 0.10% | +14.4% |
| Q3 2019 | $91,443,000 | +28.3% | 66,555,000 | +23.5% | 0.09% | +36.4% |
| Q2 2019 | $71,274,000 | -12.7% | 53,905,000 | -12.3% | 0.07% | -18.5% |
| Q1 2019 | $81,630,000 | +5.0% | 61,500,000 | -5.6% | 0.08% | -4.7% |
| Q4 2018 | $77,766,000 | -39.9% | 65,145,000 | -13.5% | 0.08% | -27.4% |
| Q3 2018 | $129,343,000 | +6.0% | 75,285,000 | -10.2% | 0.12% | -1.7% |
| Q2 2018 | $122,059,000 | – | 83,875,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| III Capital Management | 12,500,000 | $17,262,000 | 3.12% |
| CSS LLC/IL | 24,395,000 | $33,616,000 | 1.59% |
| Mint Tower Capital Management B.V. | 9,000,000 | $12,407,000 | 1.46% |
| Context Partners Fund, L.P. | 3,000,000 | $4,125,000 | 0.90% |
| Context Capital Management, LLC | 3,000,000 | $4,125,000 | 0.90% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,258,000 | $5,971,000 | 0.71% |
| SSI INVESTMENT MANAGEMENT LLC | 5,888,000 | $8,100,000 | 0.70% |
| Aequim Alternative Investments LP | 3,000,000 | $4,155,000 | 0.55% |
| WOLVERINE ASSET MANAGEMENT LLC | 32,181,000 | $44,437,000 | 0.40% |
| TWO SIGMA SECURITIES, LLC | 13,000,000 | $17,875,000 | 0.36% |